Business Context and Reporting Period
This Form 8-K, dated May 9, 2017, reports material events for Novus Therapeutics, Inc. (formerly Tokai Pharmaceuticals, Inc.). The filing documents the completion of a transformative acquisition of Otic Pharma, Ltd., a concurrent private placement of equity, a reverse stock split, a corporate name change, and a change in independent auditors. The company's primary business focus shifted to the development of ear, nose, and throat (ENT) product candidates following the acquisition.
Key Financial Metrics and Capital Structure
- Capital Raised: The company closed a stock purchase agreement on May 10, 2017, issuing 3,603,601 shares at $1.11 per share, raising approximately $4,000,000.
- Acquisition Consideration: To acquire Otic Pharma, the company issued 36,249,237 shares of common stock on May 9, 2017. The filing does not provide a specific dollar valuation for this stock consideration.
- Share Count: Immediately following the Otic Transaction and prior to the reverse split, there were 58,890,886 shares outstanding. Post-split (1-for-9), the company expects approximately 7 million shares outstanding.
- Ownership Structure: Following the Otic Transaction, the sellers beneficially owned approximately 61.6% of the outstanding shares.
- Liquidity and Debt: The filing does not provide specific data on cash balances, debt levels, or liquidity metrics. Financial statements for the acquired business are incorporated by reference from a Proxy Statement.
Material Changes Versus Prior Period
- Corporate Identity: The company changed its name from Tokai Pharmaceuticals, Inc. to Novus Therapeutics, Inc. The NASDAQ trading symbol changed from "TKAI" to "NVUS" effective May 11, 2017.
- Capital Structure: A 1-for-9 reverse stock split was implemented effective May 11, 2017, reducing the number of outstanding shares.
- Leadership: The Board of Directors was reconstituted. Four former directors resigned, and six new directors were appointed. Gregory J. Flesher was appointed CEO, Christine G. Ocampo as CFO, and Catherine C. Turkel as Chief Development Officer.
- Accounting Firm: PricewaterhouseCoopers LLP was dismissed as the independent auditor, and Ernst & Young LLP was appointed effective May 10, 2017.
Guidance, Outlook, and Risks
- Business Outlook: The company's business is now primarily that of Otic Pharma, focusing on ENT product candidates.
- Lock-Up Agreements: All sellers in the Otic Transaction are subject to 180-day lock-up agreements restricting the sale or transfer of shares.
- Registration Rights: The company entered into a Registration Rights Agreement to file a Form S-3 to register the shares issued in the $4 million private placement.
- Financial Reporting: Unaudited interim financial statements for Otic Pharma and pro forma financial information are not included in this filing but are expected to be filed as an amendment by July 25, 2017.
- Executive Compensation: New employment agreements for the CEO and CFO are expected, with current Otic agreements providing base salaries of $400,000 and $255,000, respectively.
Investor Verification Checklist
- Verify the final post-split share count and the exact closing price of the stock on May 10, 2017, to calculate the value of fractional share cash payments.
- Review the Proxy Statement (Schedule 14A) for the full audited financial statements of Otic Pharma and the detailed terms of the Share Purchase Agreement.
- Monitor the upcoming amendment to this 8-K for the unaudited interim financial statements and pro forma financial information due by July 25, 2017.
- Confirm the status of the Form S-3 registration statement for the shares issued in the private placement.
- Review the new employment agreements for the CEO and CFO once executed to confirm final compensation terms.